The observation that dasatinib is also known to target c-SRC raises the possibility that inhibition of a key negative regulatory element of SRC proteins may be responsible for the lack of dasatinib sensitivity to tumor cells over expressing c-SRC. The gene discussed is SRC; the disease is neoplasm.